USPTO issues new patent for Advaxis' intellectual property portfolio

The U.S. Patent and Trademark Office (USPTO) issued today patent 7,635,479, "Compositions and Methods for Enhancing the Immunogenicity of Antigens,” by Dr. Yvonne Paterson, et al, which is assigned to the Trustees of the University of Pennsylvania and licensed to Advaxis, Incorporated (OTCBB: ADXS).

“As we develop the intellectual property portfolio associated with our technology, this patent integrates nicely with our LLO- and ActA-antigen patents”

Research, originating in the laboratory of Dr. Yvonne Paterson and continued at Advaxis and elsewhere, has shown that the unique protein pattern called PEST (Proline, Glutamic Acid , Serine, Threonine) is associated with therapeutic efficacy in live Listeria monocytogenes (Lm)vaccines that are engineered to secrete antigen-adjuvant fusion proteins when either LLO (listeriolysin O) or ActA are used as the adjuvant.

“As we develop the intellectual property portfolio associated with our technology, this patent integrates nicely with our LLO- and ActA-antigen patents,” said Executive VP of Science and Operations Dr. John Rothman. “Our portfolio includes patents for three different attenuated vaccine strains of Listeria and two different families of fusion proteins.”

The Company’s flagship Lm strain is currently in clinical testing for human papilloma virus (HPV)-induced disease, including cancer of the cervix.